Cogent Biosciences, Inc.
NASDAQ:COGT
10.05 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cogent Biosciences, Inc. |
Symbool | COGT |
Munteenheid | USD |
Prijs | 10.05 |
Beurswaarde | 1,099,972,500 |
Dividendpercentage | 0% |
52-weken bereik | 3.67 - 12.61 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Andrew R. Robbins M.B.A. |
Website | https://www.cogentbio.com |
An error occurred while fetching data.
Over Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)